DNA minor groove adenine-N3 alkylation (via duocarmycin derivative)

The entry "DNA alkylation via duocarmycin derivative released intracellularly" does not describe a classical therapeutic target such as a protein, receptor, enzyme, or nucleic acid sequence; rather, it refers to a **mechanism of chemical DNA modification** mediated by a class of small molecules known as duocarmycins. Duocarmycin derivatives are cytotoxic DNA-alkylating agents that bind the DNA minor groove, preferentially at AT-rich regions, and covalently alkylate the N3 position of adenine residues. This DNA modification causes irreversible DNA damage, activates cell death pathways, and is potently tumoricidal, particularly when delivered as a prodrug or as a component of antibody-drug conjugates (ADCs) for targeted cancer therapy[1][7][9][2][6]. Duocarmycin-based payloads have yielded clinically relevant ADCs (e.g., SYD985), where the duocarmycin derivative is released intracellularly upon tumor targeting. The mechanism belongs to the broader class of DNA-damaging chemotherapeutics and is not itself a druggable biological target in the classical sense.

Other names

DNA alkylation (duocarmycin-class)Duocarmycin-mediated DNA alkylation

Sequence-selective alkylation of DNA at adenine N3 in the minor groove by duocarmycin derivatives, leading to irreversible DNA damage, activation of DNA damage response pathways, cell cycle arrest, and apoptosis[1][7][9][6]